Cargando…

The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee

Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397667/
https://www.ncbi.nlm.nih.gov/pubmed/27123906
http://dx.doi.org/10.18553/jmcp.2016.16071
_version_ 1785083951718596608
collection PubMed
description Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidence-based dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.
format Online
Article
Text
id pubmed-10397667
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103976672023-08-04 The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee J Manag Care Spec Pharm Viewpoints Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidence-based dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach. Academy of Managed Care Pharmacy 2016-05 /pmc/articles/PMC10397667/ /pubmed/27123906 http://dx.doi.org/10.18553/jmcp.2016.16071 Text en © 2016, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Viewpoints
The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title_full The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title_fullStr The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title_full_unstemmed The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title_short The AMCP Format for Formulary Submissions: Welcome to Version 4.0: The AMCP Format Executive Committee
title_sort amcp format for formulary submissions: welcome to version 4.0: the amcp format executive committee
topic Viewpoints
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397667/
https://www.ncbi.nlm.nih.gov/pubmed/27123906
http://dx.doi.org/10.18553/jmcp.2016.16071